地加瑞克治疗住院退伍军人COVID-19的II期随机对照试验方案
本研究为随机、双盲、安慰剂对照II期试验,计划入组198例因COVID-19住院的男性退伍军人,按2:1随机接受地加瑞克联合最佳支持治疗或安慰剂联合最佳支持治疗。主要复合终点为随机化后15天时的死亡、持续住院或需要机械通气。试验旨在验证雄激素抑制通过降低TMPRSS2表达改善COVID-19临床结局的假设。
要点
- 地加瑞克为FDA批准的LHRH拮抗剂,通过抑制雄激素受体信号降低TMPRSS2表达。
- 纳入标准为鼻咽拭子RT-PCR确诊SARS-CoV-2感染且病情严重程度3-5级(住院但无需有创机械通气)。
- 主要终点为随机化后15天死亡、持续住院或需要机械通气的复合终点。
核心结论
- 试验旨在确定单剂地加瑞克暂时性雄激素抑制能否改善COVID-19住院患者的临床结局。
研究设计与样本
- 随机、双盲、安慰剂对照II期临床试验,计划入组198例因COVID-19住院的男性退伍军人。
- 患者按年龄、高血压病史和病情严重程度分层,中央随机2:1分配至地加瑞克组或安慰剂组。
- 两组均接受最佳支持治疗。
关键数值与推荐
- 纳入标准:鼻咽拭子RT-PCR阳性确诊SARS-CoV-2感染,病情严重程度3-5级(住院但无需有创机械通气)。
- 主要复合终点:随机化后15天时的死亡、持续住院或需要机械通气。
- 重要次要终点包括临床改善时间、住院死亡率、住院时长、机械通气时长、体温恢复正常时间和COVID-19最大严重程度。
临床怎么用
- 探索性分析将评估细胞因子、病毒载量与各种合并症与结局的关联,并研究靶组织中TMPRSS2表达及抗病毒抗体产生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface protease. Pre-clinical and correlative data in humans suggest that anti-androgenic therapies can reduce the expression of TMPRSS2 on lung epithelium. Accordingly, we hypothesize that therapeutic targeting of androgen receptor signaling via degarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, will suppress COVID-19 infection and ameliorate symptom severity. METHODS: This is a randomized phase 2, placebo-controlled, double-blind clinical trial in 198 patients to compare efficacy of degarelix plus best supportive care versus placebo plus best supportive care on improving the clinical outcomes of male Veterans who have been hospitalized due to COVID-19. Enrolled patients must have documented infection with SARS-CoV-2 based on a positive reverse transcriptase polymerase chain reaction result performed on a nasopharyngeal swab and have a severity of illness of level 3-5 (hospitalized but not requiring invasive mechanical ventilation). Patients stratified by age, history of hypertension, and severity are centrally randomized 2:1 (degarelix: placebo). The composite primary endpoint is mortality, ongoing need for hospitalization, or requirement for mechanical ventilation at 15 after randomization. Important secondary endpoints include time to clinical improvement, inpatient mortality, length of hospitalization, duration of mechanical ventilation, time to achieve a normal temperature, and the maximum severity of COVID-19 illness. Exploratory analyses aim to assess the association of cytokines, viral load, and various comorbidities with outcome. In addition, TMPRSS2 expression in target tissue and development of anti-viral antibodies will also be investigated. DISCUSSION: In this trial, we repurpose the FDA approved LHRH antagonist degarelix, commonly used for prostate cancer, to suppress TMPRSS2, a host cell surface protease required for SARS-CoV-2 cell entry. The objective is to determine if temporary androgen suppression with a single dose of degarelix improves the clinical outcomes of patients hospitalized due to COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov NCT04397718. Registered on May 21, 2020.
引用
- Nickols NG, Goetz MB, Graber CJ, et al. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34225789. doi:10.1186/s13063-021-05389-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。